Heart disease kills more women than any other condition in the United States. It has done so for decades. And for much of that time, it has been treated — culturally, clinically, and in the research literature — as a man’s disease.
The consequences of that assumption are embedded in the data: women who present with heart attacks are diagnosed later, treated less aggressively, and die at higher rates following cardiac events than men. Women are less likely to receive guideline-directed therapy. Women are underrepresented in cardiovascular clinical trials. Women’s symptoms — which often differ from the classic “crushing chest pain” profile established in male-dominant research — are dismissed, minimized, or misattributed to anxiety, stress, or gastrointestinal complaints.
None of this is inevitable. All of it reflects choices — in research design, in clinical training, in the assumptions encoded in diagnostic criteria.
The Biology Is Different
Sex differences in cardiovascular disease are not trivial or peripheral. They are central to understanding why the current approach fails women.
Women’s hearts are anatomically different from men’s. Coronary arteries are smaller. Plaque distribution differs. Microvascular disease — diffuse narrowing of the small blood vessels that supply the heart — affects women at higher rates and is frequently missed by angiography, which remains the standard diagnostic tool despite being better suited to detect the large-vessel blockages more common in men.
Hormones affect cardiovascular risk across the lifespan in ways that clinical protocols have been slow to incorporate. The risk increase associated with menopause is real and clinically significant. Pregnancy complications — preeclampsia, gestational hypertension, gestational diabetes — predict future cardiovascular disease with meaningful precision, yet these histories are rarely integrated into long-term cardiac risk assessment.
Autoimmune diseases, which disproportionately affect women, carry elevated cardiovascular risk that is inadequately recognized in primary care and cardiology practice. Rheumatoid arthritis, lupus, and psoriatic arthritis all increase heart disease risk through inflammatory pathways that interact with standard risk factors in ways the field is still characterizing.
Stigma and Silence
Women who have survived heart attacks describe a consistent experience: they were not believed. Their symptoms were attributed to panic, heartburn, or hypochondria. Some drove themselves to the hospital. Some were sent home from emergency departments and returned hours later in full cardiac arrest.
Sharing these stories is not just cathartic. It is epidemiologically important. Understanding that women delay seeking care — often because they have been trained to doubt their own symptoms in medical settings — is essential to designing interventions that actually work.
The Society for Women’s Health Research has documented this pattern extensively in its Women’s Health Perspectives series. The accounts are consistent across geography, age, and race: women internalize the message that heart disease is not their disease, and when it arrives, they are unprepared — and the system is unprepared for them.
What Disruption Looks Like Here
Fix the clinical training. Medical education still teaches cardiovascular disease using male-dominant case studies, imaging benchmarks calibrated to male anatomy, and risk calculators that underperform for women. Every cardiovascular curriculum should include sex differences as a core module, not an afterthought.
Demand sex-disaggregated trial data. Cardiovascular drugs should be required to demonstrate safety and efficacy in women before approval — with dosing protocols that reflect women’s metabolic differences. This is not radical. It is basic science.
Expand microvascular disease recognition. ISCHEMIA and subsequent trials have documented that microvascular dysfunction is prevalent and clinically significant in women. Imaging protocols and referral criteria should reflect this reality.
Integrate pregnancy history into cardiac risk. Preeclampsia, gestational hypertension, and gestational diabetes are not obstetric complications that resolve at delivery. They are cardiovascular risk markers for the next 30 years of a woman’s life. A woman who experienced preeclampsia should have that history tracked in her cardiac record and factored into her preventive care.
The science is there. The political will to implement it — across training programs, guideline committees, insurance coverage decisions, and research funding priorities — is what requires disruption.
